AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
NHI

National Health Investors Inc. Common Stock (NHI) fair value

Real Estate · REIT - Healthcare Facilities · NYSE · United States
$67.06+0.15%
Market cap $3.3BNext earnings 2026-11-09Updated Oct 18, 2026
Add earnings to calendarGoogle
Our verdict
Trades 25% above our fair value
Price
$67.06
Model fair valueConfidence: good
$53.50
Model range
$48.66 to $58.35
Fair value $53.50
Price $67.06
2 models fit National Health Investors Inc. Common Stock and they agree: 2 of 2 land within 15% of the average. The price is above every model.
Two or more of our models back this value.
Premium(i)Bronze48
Valued as a REIT (property company): Price to FFO, Dividend discount, and EV/EBITDA comparison.
ACCE opinionNational Health Investors Inc. Common Stock (NHI)
Fair value (2 models)
$53.50
ACCE price target
$65.00
Rating
Overvalued
Horizon
12 months
Fair value published on 14 Oct 2026, 00:00 CEST; previously $52.40 since 9 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 16:04 CEST.
Price used: $67.06 at the close on 23 Oct 2026, 22:00 CEST.
Models: Dividend discount, EV/EBITDA comparison, and Price to FFO.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
25.3% above
-20.2% to fair value
ACCE score
68
out of 100
Analysts
63% buy
8 covering
P/E
18.8x
forward 18.1x
1-year return
-11.0%
Dividend yield
5.67%

National Health Investors Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

National Health Investors owns a portfolio of senior housing, skilled nursing and medical office properties, mostly leased on long-term triple-net terms that push maintenance, taxes and insurance onto the operator. That structure, plus a tenant base concentrated in established regional operators, gives the rent stream unusually high visibility and a gross margin near 74%. The near-term story is the 33.8% revenue growth, which reflects acquisitions and rent escalators rather than organic demand alone, so the question for a deeper look is how much of that growth is accretive after funding costs. At 19.2x trailing and 18.1x forward earnings, the stock is priced for steady compounding rather than a re-rating, and a 10.7% ROE says the equity base is not yet earning much above its cost. It is worth a closer look if the balance sheet and tenant coverage hold up under a higher-rate environment; the score of 67/100 suggests the case is solid but not yet compelling.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 1 flagAI-assisted·How I use AI
  • moderate
    Thin revenue history behind the rally
    Revenue grew 33.8% year on year, but the five-year CAGR is only 2.6%, so the recent jump may not persist. Margin compression is not visible in the data, but the growth base is narrow.

AI research notes

AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last twelve months reached $220M, a cash base that supports the dividend.
  • The dividend yield of 5.7% is high, and 63% of covering analysts rate the stock Buy or Strong Buy.
Why it could disappoint
  • Return on equity of 10.7% and return on invested capital of 4.3% are thin for the capital tied up in the business.
  • The diluted share count rose 6.7% last fiscal year, diluting each shareholder's slice of future cash flow.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 9, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where NHI's valuation models land
Price
$67.06
Model fair value
$53.50
Model range
$48.66 to $58.35
Fair value $53.50
Price $67.06
The price is above the whole model range.
Model
Fair value
Upside
Dividend discount
EV/EBITDA comparison
Price to FFO
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish63% buy · 8 covering analysts
● Strong buy 5● Buy 0● Hold 3● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
1 buy · 0 sells
Since Jul 10, 2026, 1 member
Average delay
35 days
From trade to public filing
Full trade list on ProDo politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+1.2%
1 month
-0.2%
3 months
-16.7%
6 months
-12.9%
YTD
-12.2%
1 year
-11.0%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
18 Oct 2026, 16:04 CESTRatingOvervaluedfirst publication$66.28
14 Oct 2026, 00:00 CESTFair value$53.86$52.40$65.62
11 Oct 2026, 00:00 CESTACCE price target$65.00first publication$64.85
9 Oct 2026, 00:00 CESTFair value$52.40$53.37$63.96
29 Sept 2026, 00:00 CESTFair value$53.37$52.34$66.92
18 Sept 2026, 00:00 CESTFair value$52.34$53.05$68.16
15 Sept 2026, 00:00 CESTFair value$53.05$53.74$70.32
2 Sept 2026, 00:00 CESTFair value$53.74$54.32$71.11
30 Aug 2026, 00:00 CESTFair value$54.32$65.86$72.03
5 Aug 2026, 00:00 CESTFair value$65.86$67.29$74.95

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full NHI page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth100Value65Quality81Momentum25Total68
Valuation
Trailing P/E
18.8x
Forward P/E
18.1x
PEG
4.76
P/B
2.10x
EV / Revenue
10.5x
Book value/sh
$31.99
Enterprise value
$4.5B
Profitability
ROE
10.7%
FCF yield
6.70%
ROIC
4.3%
Health and risk
Debt / equity
0.76
Dividend yield
5.67%
Beta
0.52

Price

-10.8% · 1Y

Ask anything about NHI

Answered from National Health Investors Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 20% of peers
low 0.0x18.8xhigh 78.2x
ROEbetter than 83% of peers
low -15%11%high 12%
Div yieldbetter than 50% of peers
low 0.5%5.7%high 13.3%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
NHI National Health Investors Inc. Common Stock$67.06$5425% above18.8x10.7%8168
PHP.L Primary Health Properties Plc£0.92£176% above15.2x8.1%7660
LTC LTC Properties Inc. Common Stock$43.75$3621% above15.2x11.8%8183
SBRA Sabra Health Care REIT Inc. Common Stock$19.56--78.2x2.4%4445
DHC Diversified Healthcare Trust Common Shares of Beneficial Interest$7.86----15.5%2632
HR Healthcare Realty Trust Incorporated Common Stock$17.95$1165% above--1.9%4736
MPT Medical Properties Trust Inc. common stock$2.70----0.6%5039

Sector report card

Where NHI ranks against its sector peers on each metric.

Computing percentiles…
  • PR Newswire•Oct 7, 2026
    NHI Announces Third Quarter 2026 Earnings Release and Conference Call Dates
  • PR Newswire•Oct 1, 2026
    NHI Announces $107.7 Million SHOP Investment
  • PR Newswire•Sep 14, 2026
    NHI to Participate in the BofA Securities 2026 Global Real Estate Conference; Updates Pipeline
5 more press releases · full archive on Investor+.INVESTOR
40 filings
August 2026
Aug 27
8-KCurrent reportPeriod 2026-08-27
View on SEC →
Aug 10
8-KCurrent reportPeriod 2026-08-10
View on SEC →
Aug 10
8-KCurrent reportPeriod 2026-08-10
View on SEC →
37 more filings + AI summaries on Investor+.INVESTOR